Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3231)	3/29/2001 3:26:27 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

Somewhat OT, but I think the TSC interview with Ravi Suria is an excellent read: thestreet.com He makes the point that a lot of the GNP growth over the last few years has been investment driven, and the money for that has now dried up and is not likely to return any time soon. You could well argue that a company like CRA is analogous. Of course the biotechs are largely unsaddled with debt, with the exception of some that went for convertibles instead of stock. A further point of differentiation is that the underlying biotech business model is generally sound. Peter